Skip to main content
Top
Published in: Clinical Research in Cardiology 11/2014

01-11-2014 | Original Paper

Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database

Authors: Pierre Sabouret, Leyla Depret-Bixio, François-Emery Cotte, Pierre Marie, Nabil Bedira, Patrick Blin

Published in: Clinical Research in Cardiology | Issue 11/2014

Login to get access

Abstract

Background and objectives

Most of the French patients diagnosed with atrial fibrillation (AF) are managed by general practitioners (GPs). The objective was to evaluate stroke prevention in AF patients ahead of the arrival of the non vitamin K oral anticoagulant in France.

Methods

A cross-sectional study using a French GPs database of all patients with a diagnosis of AF consulting their GP between July-2010 and June-2011. Multivariate analyses were used to identify determinants of prevention prescription.

Results

Among 15,623 AF patients, 42.5 % were ≥75 years and 40.5 % women, 59.2 % had hypertension, 17.2 % diabetes, 11.4 % heart failure, 4.9 % stroke history. CHADS2 score was ≥1 for 83.1 % and ≥2 for 50.9 % of patients (CHA2DS2-VASc score ≥1 for 93.7 % and ≥2 for 82.3 %). Antithrombotic therapies were vitamin K antagonists (VKA) for 50.7 % of patients, followed by aspirin for 19.9 %, clopidogrel ± aspirin for 4.3 % and none for 25.1 %. For patients with CHADS2 scores ≥1, 73.3 % received an antithrombotic and for those with CHADS2 scores ≥2, 54.9 % were treated by a VKA. An age-stratified multivariate analysis showed that women had an odds ratio to be treated with VKA compared to 0.83 (95 % CI: 0.72–0.95) and 0.66 (95 % CI: 0.59–0.74) when aged <75 years and ≥75 years, respectively.

Conclusions

Most AF patients followed by French GPs required stroke prevention according to European guidelines, but many of them did not receive the recommended antithrombotic treatment. Women over 75 were a third less likely to be treated with recommended anticoagulants than men of similar age.
Literature
1.
go back to reference Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRef Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRef
2.
go back to reference Sandhu RK, McAlister FA (2013) Stroke prevention for patients with atrial fibrillation: improving but not perfect yet. Heart 99:1141PubMedCrossRef Sandhu RK, McAlister FA (2013) Stroke prevention for patients with atrial fibrillation: improving but not perfect yet. Heart 99:1141PubMedCrossRef
3.
go back to reference Charlemagne A, Blacher J, Cohen A, Collet J-P et al (2011) Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis 104:115–124PubMedCrossRef Charlemagne A, Blacher J, Cohen A, Collet J-P et al (2011) Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis 104:115–124PubMedCrossRef
4.
go back to reference HAS (2013) Haute Autorité de Santé. Eliquis. Commission de la Transparence Avis, 12 juin 2013 HAS (2013) Haute Autorité de Santé. Eliquis. Commission de la Transparence Avis, 12 juin 2013
5.
go back to reference Camm AJ, Kirchhof P, Lip GYH, Schotten U et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Europace 12:1360–1420PubMedCrossRef Camm AJ, Kirchhof P, Lip GYH, Schotten U et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Europace 12:1360–1420PubMedCrossRef
6.
go back to reference Camm AJ, Lip GYH, De Caterina R, Savelieva I et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European heart rhythm association. Eur Heart J 33:2719–2747PubMedCrossRef Camm AJ, Lip GYH, De Caterina R, Savelieva I et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European heart rhythm association. Eur Heart J 33:2719–2747PubMedCrossRef
7.
go back to reference Volgman AS, Manankil MF, Mookherjee D, Trohman RG (2009) Women with atrial fibrillation: greater risk, less attention. Gend Med 6:419–432PubMedCrossRef Volgman AS, Manankil MF, Mookherjee D, Trohman RG (2009) Women with atrial fibrillation: greater risk, less attention. Gend Med 6:419–432PubMedCrossRef
8.
go back to reference Humphries KH, Kerr CR, Connolly SJ, Klein G et al (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103:2365–2370PubMedCrossRef Humphries KH, Kerr CR, Connolly SJ, Klein G et al (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103:2365–2370PubMedCrossRef
9.
go back to reference Carlsson A, Wändell P, Sundquist K, Johansson S-E et al (2013) Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations. Eur J Clin Pharmacol 69:245–253PubMedCrossRef Carlsson A, Wändell P, Sundquist K, Johansson S-E et al (2013) Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations. Eur J Clin Pharmacol 69:245–253PubMedCrossRef
10.
go back to reference Gage BF, Boechler M, Doggette AL, Fortune G et al (2000) Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 31:822–827PubMedCrossRef Gage BF, Boechler M, Doggette AL, Fortune G et al (2000) Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 31:822–827PubMedCrossRef
11.
go back to reference Cohen A, Dallongeville J, Durand-Zaleski I, Bouée S et al (2010) Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 103:376–387PubMedCrossRef Cohen A, Dallongeville J, Durand-Zaleski I, Bouée S et al (2010) Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 103:376–387PubMedCrossRef
12.
go back to reference Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F et al (2011) Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data. Ann Pharmacother 45:179–188 Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F et al (2011) Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data. Ann Pharmacother 45:179–188
13.
go back to reference Cotté FE, Fardellone P, Mercier F, Gaudin AF et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155PubMedCrossRefPubMedCentral Cotté FE, Fardellone P, Mercier F, Gaudin AF et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155PubMedCrossRefPubMedCentral
14.
go back to reference Fourcade R-O, Lacoin F, Rouprêt M, Slama A et al (2012) Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol 30:419–426PubMedCrossRefPubMedCentral Fourcade R-O, Lacoin F, Rouprêt M, Slama A et al (2012) Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol 30:419–426PubMedCrossRefPubMedCentral
15.
go back to reference Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley, Chichester Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley, Chichester
16.
go back to reference Nieuwlaat R, Capucci A, Camm AJ, Olsson SB et al (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J 26:2422–2434PubMedCrossRef Nieuwlaat R, Capucci A, Camm AJ, Olsson SB et al (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J 26:2422–2434PubMedCrossRef
17.
go back to reference Cowan C, Healicon R, Robson I, Long WR et al (2013) The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 99(16):1166–1172PubMedCrossRefPubMedCentral Cowan C, Healicon R, Robson I, Long WR et al (2013) The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 99(16):1166–1172PubMedCrossRefPubMedCentral
18.
go back to reference Friberg L, Hammar N, Ringh M, Pettersson H et al (2006) Stroke prophylaxis in atrial fibrillation: who gets it and who does not? report from the Stockholm cohort-study on atrial fibrillation (SCAF-study). Eur Heart J 27:1954–1964PubMedCrossRef Friberg L, Hammar N, Ringh M, Pettersson H et al (2006) Stroke prophylaxis in atrial fibrillation: who gets it and who does not? report from the Stockholm cohort-study on atrial fibrillation (SCAF-study). Eur Heart J 27:1954–1964PubMedCrossRef
19.
go back to reference Ogilvie IM, Newton N, Welner SA, Cowell W et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(638–645):e4PubMed Ogilvie IM, Newton N, Welner SA, Cowell W et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(638–645):e4PubMed
20.
go back to reference Arts DL, Visscher S, Opstelten W, Korevaar JC et al (2013) Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice. PLoS One 8:e67806PubMedCrossRefPubMedCentral Arts DL, Visscher S, Opstelten W, Korevaar JC et al (2013) Frequency and risk factors for under- and over-treatment in stroke prevention for patients with non-valvular atrial fibrillation in general practice. PLoS One 8:e67806PubMedCrossRefPubMedCentral
21.
go back to reference Conen D, Glynn RJ, Sandhu RK, Tedrow UB et al (2013) Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. Int J Cardiol 168(3):1894–1899PubMedCrossRefPubMedCentral Conen D, Glynn RJ, Sandhu RK, Tedrow UB et al (2013) Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. Int J Cardiol 168(3):1894–1899PubMedCrossRefPubMedCentral
22.
go back to reference Fang MC, Singer DE, Chang Y, Hylek EM et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687–1691PubMedCrossRefPubMedCentral Fang MC, Singer DE, Chang Y, Hylek EM et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687–1691PubMedCrossRefPubMedCentral
23.
go back to reference Karasoy D, Bo Jensen T, Hansen ML, Schmiegelow M et al (2013) Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace 15:781–786PubMedCrossRef Karasoy D, Bo Jensen T, Hansen ML, Schmiegelow M et al (2013) Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study. Europace 15:781–786PubMedCrossRef
24.
go back to reference Tsadok AM, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L (2012) Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 307:1952–1958CrossRef Tsadok AM, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L (2012) Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 307:1952–1958CrossRef
25.
go back to reference Atrial fibrillation Investigators (AFI) (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRef Atrial fibrillation Investigators (AFI) (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRef
26.
go back to reference Alotaibi GS, Almodaimegh H, McMurtry MS, Wu C (2013) Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? a sex-based meta-analysis. Thrombosis Res 132:185–189CrossRef Alotaibi GS, Almodaimegh H, McMurtry MS, Wu C (2013) Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? a sex-based meta-analysis. Thrombosis Res 132:185–189CrossRef
27.
go back to reference Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M et al (2006) Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 27:1947–1953PubMedCrossRef Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M et al (2006) Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J 27:1947–1953PubMedCrossRef
28.
go back to reference Mellemkjær L, Blot WJ, Sørensen HT, Thomassen L et al (2002) Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 53:173–181PubMedCrossRefPubMedCentral Mellemkjær L, Blot WJ, Sørensen HT, Thomassen L et al (2002) Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 53:173–181PubMedCrossRefPubMedCentral
30.
go back to reference Meinertz T, Kirch W, Rosin L, Pittrow D et al (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 100:897–905PubMedCrossRefPubMedCentral Meinertz T, Kirch W, Rosin L, Pittrow D et al (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 100:897–905PubMedCrossRefPubMedCentral
31.
go back to reference de Lusignan S, van Vlymen J, Hague N, Thana L, Dzregah B, Chan T (2005) Preventing stroke in people with atrial fibrillation: a cross-sectional study. J Public Health (Oxf) 27:85–92CrossRef de Lusignan S, van Vlymen J, Hague N, Thana L, Dzregah B, Chan T (2005) Preventing stroke in people with atrial fibrillation: a cross-sectional study. J Public Health (Oxf) 27:85–92CrossRef
32.
go back to reference Barrios V, Calderón A, Escobar C, de la Figuera M, Primary care group in the clinical cardiology section of the Spanish society of cardiology (2012) Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol (Engl Ed) 65:47–53CrossRef Barrios V, Calderón A, Escobar C, de la Figuera M, Primary care group in the clinical cardiology section of the Spanish society of cardiology (2012) Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol (Engl Ed) 65:47–53CrossRef
33.
go back to reference Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA et al (2013) Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 8:e63479PubMedCrossRefPubMedCentral Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA et al (2013) Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 8:e63479PubMedCrossRefPubMedCentral
34.
go back to reference Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef
35.
go back to reference Ganse EV, Letrilliart L, Borne H, Morand F et al (2012) Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program. Pharmacoepidemiol Drug Saf 21:261–268PubMedCrossRef Ganse EV, Letrilliart L, Borne H, Morand F et al (2012) Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program. Pharmacoepidemiol Drug Saf 21:261–268PubMedCrossRef
36.
go back to reference Le Ray I, Barkun AN, Vauzelle-Kervroedan F, Bardou M (2013) Failure to renew prescriptions for gastroprotective agents to patients on continuous nonsteroidal anti-inflammatory drugs increases rate of upper gastrointestinal injury. Clin Gastroenterol Hepatol 11:499–504 e1PubMedCrossRef Le Ray I, Barkun AN, Vauzelle-Kervroedan F, Bardou M (2013) Failure to renew prescriptions for gastroprotective agents to patients on continuous nonsteroidal anti-inflammatory drugs increases rate of upper gastrointestinal injury. Clin Gastroenterol Hepatol 11:499–504 e1PubMedCrossRef
Metadata
Title
Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database
Authors
Pierre Sabouret
Leyla Depret-Bixio
François-Emery Cotte
Pierre Marie
Nabil Bedira
Patrick Blin
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 11/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0726-y

Other articles of this Issue 11/2014

Clinical Research in Cardiology 11/2014 Go to the issue